Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

M. Rizzo, F. Morelli, Y. Ürün, S. Buti, SH. Park, MT. Bourlon, E. Grande, F. Massari, J. Landmesser, A. Poprach, H. Takeshita, G. Roviello, ZW. Myint, L. Popovic, A. Soares, H. Abahssain, P. Giannatempo, J. Molina-Cerrillo, L. Incorvaia, S....

. 2025 ; 14 (4) : e70479. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25009980

BACKGROUND: Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody-drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory to platinum and immune-checkpoint inhibitor (ICI) therapy. Our study provides a retrospective, international, real-world analysis comparing the effectiveness of EV to chemotherapy in this setting. METHODS: The data were extracted from the medical records of patients treated with EV or chemotherapy following pembrolizumab for recurrent or progressive aUC after platinum-based chemotherapy. Patients were assessed for overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR). RESULTS: Our analysis included 247 patients treated with EV (88, 36%) or chemotherapy (159, 64%). Median OS was 9.1 months (95%CI 7.2-10.7) in the overall study population, 13.6 months (95%CI 10.0-31.0) in patients receiving EV and 6.8 months (95%CI 6.0-8.9) in patients receiving chemotherapy (p < 0.001). The OS benefit of EV was not affected by primary tumour site and histology, metastatic sites, type of first platinum-based chemotherapy or response to pembrolizumab. In the EV cohort, the median PFS was significantly longer (8.8 months [95%CI 6.5-17.0] vs. 3.0 months [95%CI 2.6-3.7]) and the ORR was significantly higher (56% vs. 23%) than in the chemotherapy cohort. CONCLUSIONS: The results of our international analysis of real-world data confirm the effectiveness of EV in the sequential strategy of aUC patients who have received prior platinum-based chemotherapy and anti-PD-1 pembrolizumab, regardless of commonly considered prognostic factors. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05290038.

Chair of Oncology Interdisciplinary Department of Medicine University of Bari Aldo Moro Bari Italy

Department of Adult Medical Oncology King Fahad Specialist Hospital Dammam Dammam Saudi Arabia

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Health Sciences Section of Clinical Pharmacology and Oncology University of Florence Florence Italy

Department of Hemato Oncology Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran Universidad Panamericana Mexico City Mexico

Department of Medical and Surgical Sciences University of Bologna Bologna Italy

Department of Medical Oncology Faculty of Medicine Ankara University Ankara Turkey

Department of Medical Oncology Hospital Ramón y Cajal Madrid Spain

Department of Medical Oncology MD Anderson Cancer Center Madrid Madrid Spain

Department of Medicine and Surgery University of Parma Parma Italy

Department of Precision Medicine in Medical Surgical and Critical Care Section of Medical Oncology University of Palermo Palermo Italy

Department of Urology Saitama Medical Center Saitama Medical University Saitama Japan

Division of Medical Oncology Department of Internal Medicine Markey Cancer Center University of Kentucky Lexington Kentucky USA

Faculty of Medicine Masaryk University Brno Czech Republic

Faculty of Medicine Oncology Institute of Vojvodina University of Novi Sad Novi Sad Serbia

Hospital Israelita Albert Einstein São Paulo Brazil

Hospital Sírio Libanês Brasília Brazil

Klinik für Urologie Universitätsklinikum Schleswig Holstein Campus Lübeck Lübeck Germany

Latin American Cooperative Oncology Group LACOG Porto Alegre Brazil

Medical Oncology Department Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Medical Oncology IRCCS Azienda Ospedaliero Universitaria di Bologna Bologna Italy

Medical Oncology Unit Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari Bari Italy

Medical Oncology Unit IRCCS Casa Sollievo della Sofferenza Foggia Italy

Medical Oncology Unit Macerata Hospital Macerata Italy

Medical Oncology Unit University Hospital of Parma Parma Italy

Medicine and Pharmacy Faculty National Institute of Oncology Medical Oncology Unit Mohamed 5 University Rabat Morocco

Niguarda Cancer Center Grande Ospedale Metropolitano Niguarda Milan Italy

Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea

Taussig Cancer Institute Cleveland Clinic Cleveland Ohio USA

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25009980
003      
CZ-PrNML
005      
20250429135257.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/cam4.70479 $2 doi
035    __
$a (PubMed)39980145
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rizzo, Mimma $u Medical Oncology Unit, Azienda Ospedaliera Universitaria Consorziale Policlinico di Bari, Bari, Italy $1 https://orcid.org/000000017743741X
245    10
$a Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience / $c M. Rizzo, F. Morelli, Y. Ürün, S. Buti, SH. Park, MT. Bourlon, E. Grande, F. Massari, J. Landmesser, A. Poprach, H. Takeshita, G. Roviello, ZW. Myint, L. Popovic, A. Soares, H. Abahssain, P. Giannatempo, J. Molina-Cerrillo, L. Incorvaia, S. Salah, A. Zeppellini, FSM. Monteiro, C. Porta, S. Gupta, M. Santoni
520    9_
$a BACKGROUND: Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody-drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevant clinical benefit in patients with aUC refractory to platinum and immune-checkpoint inhibitor (ICI) therapy. Our study provides a retrospective, international, real-world analysis comparing the effectiveness of EV to chemotherapy in this setting. METHODS: The data were extracted from the medical records of patients treated with EV or chemotherapy following pembrolizumab for recurrent or progressive aUC after platinum-based chemotherapy. Patients were assessed for overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR). RESULTS: Our analysis included 247 patients treated with EV (88, 36%) or chemotherapy (159, 64%). Median OS was 9.1 months (95%CI 7.2-10.7) in the overall study population, 13.6 months (95%CI 10.0-31.0) in patients receiving EV and 6.8 months (95%CI 6.0-8.9) in patients receiving chemotherapy (p < 0.001). The OS benefit of EV was not affected by primary tumour site and histology, metastatic sites, type of first platinum-based chemotherapy or response to pembrolizumab. In the EV cohort, the median PFS was significantly longer (8.8 months [95%CI 6.5-17.0] vs. 3.0 months [95%CI 2.6-3.7]) and the ORR was significantly higher (56% vs. 23%) than in the chemotherapy cohort. CONCLUSIONS: The results of our international analysis of real-world data confirm the effectiveness of EV in the sequential strategy of aUC patients who have received prior platinum-based chemotherapy and anti-PD-1 pembrolizumab, regardless of commonly considered prognostic factors. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05290038.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a senioři $7 D000368
650    _2
$a lidé středního věku $7 D008875
650    12
$a humanizované monoklonální protilátky $x terapeutické užití $x aplikace a dávkování $7 D061067
650    12
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a monoklonální protilátky $x terapeutické užití $x aplikace a dávkování $7 D000911
650    _2
$a urologické nádory $x farmakoterapie $x patologie $x mortalita $7 D014571
650    _2
$a karcinom z přechodných buněk $x farmakoterapie $x mortalita $x patologie $7 D002295
650    _2
$a dospělí $7 D000328
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Morelli, Franco $u Medical Oncology Unit, IRCCS Casa Sollievo della Sofferenza, Foggia, Italy
700    1_
$a Ürün, Yüksel $u Department of Medical Oncology, Faculty of Medicine, Ankara University, Ankara, Turkey
700    1_
$a Buti, Sebastiano $u Department of Medicine and Surgery, University of Parma, Parma, Italy $u Medical Oncology Unit, University Hospital of Parma, Parma, Italy $1 https://orcid.org/0000000308760226
700    1_
$a Park, Se Hoon $u Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
700    1_
$a Bourlon, Maria T $u Department of Hemato-Oncology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Universidad Panamericana, Mexico City, Mexico $1 https://orcid.org/000000023116912X
700    1_
$a Grande, Enrique $u Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain
700    1_
$a Massari, Francesco $u Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy $u Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
700    1_
$a Landmesser, Johannes $u Klinik für Urologie, Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Germany
700    1_
$a Poprach, Alexandr $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Takeshita, Hideki $u Department of Urology, Saitama Medical Center, Saitama Medical University, Saitama, Japan $1 https://orcid.org/0000000215126904
700    1_
$a Roviello, Giandomenico $u Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy
700    1_
$a Myint, Zin W $u Division of Medical Oncology, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA
700    1_
$a Popovic, Lazar $u Faculty of Medicine, Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia
700    1_
$a Soares, Andrey $u Hospital Israelita Albert Einstein, São Paulo, Brazil $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil
700    1_
$a Abahssain, Halima $u Medicine and Pharmacy Faculty, National Institute of Oncology, Medical Oncology Unit, Mohamed V University, Rabat, Morocco $1 https://orcid.org/0000000231091609
700    1_
$a Giannatempo, Patrizia $u Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
700    1_
$a Molina-Cerrillo, Javier $u Department of Medical Oncology, Hospital Ramón y Cajal, Madrid, Spain
700    1_
$a Incorvaia, Lorena $u Department of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), Section of Medical Oncology, University of Palermo, Palermo, Italy
700    1_
$a Salah, Samer $u Department of Adult Medical Oncology, King Fahad Specialist Hospital-Dammam, Dammam, Saudi Arabia $1 https://orcid.org/0000000174212522
700    1_
$a Zeppellini, Annalisa $u Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy
700    1_
$a Monteiro, Fernando Sabino Marques $u Latin American Cooperative Oncology Group-LACOG, Porto Alegre, Brazil $u Hospital Sírio-Libanês, Brasília, Brazil
700    1_
$a Porta, Camillo $u Chair of Oncology, Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy
700    1_
$a Gupta, Shilpa $u Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA
700    1_
$a Santoni, Matteo $u Medical Oncology Unit, Macerata Hospital, Macerata, Italy
773    0_
$w MED00181704 $t Cancer medicine $x 2045-7634 $g Roč. 14, č. 4 (2025), s. e70479
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39980145 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429135253 $b ABA008
999    __
$a ok $b bmc $g 2311385 $s 1247061
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 14 $c 4 $d e70479 $e - $i 2045-7634 $m Cancer medicine $n Cancer Med $x MED00181704
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace